Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to -$3646.0.

  • bioAffinity Technologies' Capital Expenditures fell 13874.6% to -$3646.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60568.0, marking a year-over-year decrease of 772.7%. This contributed to the annual value of $79083.0 for FY2024, which is 24531.05% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Capital Expenditures stood at -$3646.0, which was down 13874.6% from $13427.0 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Capital Expenditures peaked at $50786.0 during Q1 2025, and registered a low of -$13442.0 during Q4 2023.
  • For the 3-year period, bioAffinity Technologies' Capital Expenditures averaged around $14777.5, with its median value being $9410.0 (2024).
  • As far as peak fluctuations go, bioAffinity Technologies' Capital Expenditures skyrocketed by 546804.73% in 2024, and later tumbled by 13874.6% in 2025.
  • Quarter analysis of 3 years shows bioAffinity Technologies' Capital Expenditures stood at -$13442.0 in 2023, then soared by 100.01% to $1.0 in 2024, then plummeted by 364700.0% to -$3646.0 in 2025.
  • Its Capital Expenditures stands at -$3646.0 for Q3 2025, versus $13427.0 for Q2 2025 and $50786.0 for Q1 2025.